Royalty Pharma plc (RPRX) stock analysis
In our weekly check, Royalty Pharma plc is graded B (A to F). Of 25 checks on debt, profit, cash flow and trend: 20 pass, warnings: 3, red flags: 2.
About Royalty Pharma plc
Royalty Pharma plc is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as RPRX.
What our checks show for RPRX
Red flags
- Net debt is 5.2x a year of EBITDA (debt/equity 1.26). That limits room in a downturn and raises refinancing risk.
- The gross margin fell by 12.7 points, to 87.3%: costs are rising faster than prices.
Warning signs
- The net margin fell by 1.4 points over 5 years, to 25.7%: the company keeps less of each sale as profit.
- The stock has fallen as much as 54% from a peak. Would you have held through that?
- Return on capital (ROCE) is only 8.6%.
Strengths
- Operating cash flow is 4.4x net profit: the profit arrives as real cash.
- Analysts expect earnings per share to grow about 82.9% a year over the next years.
- Analysts expect revenue to grow about 23.4% a year over the next years.
- Analysts expect the net margin to improve by 60.5 points from today's 25.7%.
- Earnings per share grew 159% a year over the last 3 years.
- Net profit grew 150% a year over the last 3 years.
Next earnings report: 2027-02-10
Similar companies
CORT · KNSA · LQDA
Questions
What grade does Royalty Pharma plc (RPRX) have?
In our weekly check, Royalty Pharma plc is graded B (A to F). Of 25 checks on debt, profit, cash flow and trend: 20 pass, warnings: 3, red flags: 2. The grade is a risk check, not a buy or sell recommendation.
What are the main risks of RPRX stock?
This week's biggest flags for Royalty Pharma plc: High debt, Gross margin falling, Margins falling. In total 5 of 25 checks show a warning or a red flag.
What does Royalty Pharma plc do?
Royalty Pharma plc is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as RPRX.
When does Royalty Pharma plc report earnings next?
The next earnings report is expected on 2027-02-10. We re-run the checks every week, so the grade can change after it.
The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.
Updated 2026-11-14
Open the full analysis